Dr. Funda Meric, MD

Dr. Meric practices at The University of Texas MD Anderson Cancer Center in Houston, Texas, part of The University of Texas System.

Dr. Meric's NPI, 1306932074, was assigned on October 4, 2006. Dr. Meric graduated from Yale School of Medicine in 1991. Dr. Meric holds Texas license K7060.

Dr. Meric's primary practice is The University of Texas MD Anderson Cancer Center, at 1515 Holcombe Blvd, Houston, TX 77030.

Dr. Meric's primary practice is The University of Texas MD Anderson Cancer Center in Houston, Texas, part of The University of Texas System. The medical group on file is Physicians Referral Service.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Meric practices. Vendor and product names are available with a free account.

Surgery is Dr. Meric's primary specialty in the NPI Registry, under taxonomy code 208600000X. Dr. Meric is board certified in clinical informatics by the American Board of Preventive Medicine. Dmand AI has Dr. Meric's licenses on file in 11 states: Texas, Florida, Arizona, Georgia, Mississippi, Oklahoma, Tennessee, Alabama, Louisiana, Washington and Michigan.

Dmand AI lists breast reconstruction and mastectomy among the conditions Dr. Meric treats.

CMS data shows 177 Medicare services from Dr. Meric across 2 procedure codes in 2024, all of them office visits, for 74 Medicare patients. Medicare paid $20,418 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 74 Medicare patients who saw Dr. Meric in 2024. The largest group is 65 to 74, with 52 patients. 70% of them have cancer, and 70% have high blood pressure. Their average risk score is 3.04, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Meric's median patient age at 69, with 86% women.

In 2024, Dr. Meric wrote 39 Medicare Part D claims for 17 patients. 100% of them were for generic drugs. CMS names the drug for 15 of them, across 1 drug with 11 or more claims each, at $99 in total drug cost.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 84 out of 100 for Dr. Meric for performance year 2024, reported as part of a group. Dr. Meric accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Meric as offering telehealth.

Mastectomy: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 6 papers to Dr. Meric. The most frequent topics are Breast Neoplasms, RNA, Messenger and Signal Transduction. Dr. Meric's most frequent co-authors are Kelly K. Hunt, MD, Frederick C. Ames, MD and Barry W. Feig, MD.

Dmand AI links Dr. Meric to 23 clinical trials, 10 of them phase 1 studies. 13 are still active or recruiting. Conditions studied include Breast Neoplasms, Breast Diseases and Neoplasm Metastasis. M.D. Anderson Cancer Center sponsors the most, 7.

CMS Open Payments shows 172 general payments to Dr. Meric from 32 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 77% of the total. Genentech, Inc. paid the most, $44,092. It also lists 5 research payments totaling $4,906 from 2020 to 2023.

Dmand AI lists 4 awards for Dr. Meric, most recently America's Top Doctors in 2014.

Dr. Meric graduated from Yale School of Medicine in 1991. Dr. Meric is a member of ACS and ASCO.

Dr. Meric is in network with 8 carriers, including Aetna, Blue Cross Blue Shield of Michigan and United Healthcare. Medicare plans come from the most carriers, 4. Check the plan with the practice before a visit.